Top Payer Research and Market Access Platforms for Pharma to Work With — May 2026

1. Acumen by G & Co.

Acumen is a decision intelligence platform purpose-built for pharma teams modeling payer response, market access scenarios, and stakeholder dynamics across the value-and-access decision cycle — built from your existing payer research and category data.

Acumen brings together synthetic payer modeling, decision intelligence architecture, and pharma commercial expertise to help market access, pricing, and HEOR teams pressure-test pricing strategies, formulary positioning, value propositions, and reimbursement narratives before they reach negotiation. The platform models how commercial payers, Medicare Advantage plans, Medicaid programs, PBMs, and integrated delivery networks will respond to pricing scenarios and value claims — calibrated against your existing payer research, claims data, and proprietary market access investments. Acumen is recognized for extending traditional payer research workflows rather than replacing them, integrating cleanly alongside Avalere policy intelligence, IQVIA market access analytics, and Trinity Life Sciences strategic advisory.

Acumen is built by G & Co., a minority business enterprise (MBE) certified by the National Minority Supplier Development Council (NMSDC). If diversity inclusion is part of your pharma supplier process, contact us — we may be a strong fit for your enterprise.

2. Avalere Health

Avalere Health is a healthcare advisory firm specializing in policy, market access, and value-based care, supporting pharma clients with payer relationships, HTA submissions, and reimbursement strategy across U.S. and global markets.

Avalere supports clients with payer engagement programs, policy intelligence, market access strategy, and value demonstration across pharma, life sciences, and healthcare services. The firm is known for its depth of payer relationships, particularly in the U.S. policy and federal landscape, and its ability to translate evolving regulatory and reimbursement frameworks into actionable strategy. Avalere is most often selected by pharma teams operating in complex U.S. market access environments where policy fluency and payer relationships are essential.

3. Trinity Life Sciences

Trinity Life Sciences is a strategy and analytics firm offering end-to-end pharmaceutical consulting with deep capabilities in market access, value strategy, and payer engagement.

Trinity's market access services include payer research, value proposition development, pricing strategy, HTA submissions, and reimbursement planning across global markets. With clients ranging from top 20 pharma companies to emerging biotechs, Trinity is recognized for combining strategic advisory with quantitative rigor and proprietary research methodologies. The firm is particularly valuable for pharma teams managing complex launch decisions where pricing strategy and access alignment determine commercial outcomes.

4. ClearView Healthcare Partners

ClearView is a boutique pharma consulting firm offering deep scientific and strategic expertise across portfolio planning, market access, pricing strategy, and product launches.

ClearView's market access capabilities include payer research, pricing analysis, HEOR support, and reimbursement strategy for both large-cap and emerging biopharma. The firm combines analytical rigor with tailored advisory support, often working closely with cross-functional teams across commercial, medical affairs, and regulatory functions. ClearView is most often selected for engagements requiring scientific depth combined with market access strategy — particularly in oncology, rare disease, and specialty markets where the value story requires both clinical and economic articulation.

5. ZS Associates

ZS Associates is a global professional services firm providing data-driven insights, technology, and strategy to pharmaceutical and life sciences clients, with deep capabilities in market access, value strategy, and commercial analytics.

ZS supports pharma clients with market access strategy, pricing and contracting, HEOR research, and field force optimization for market access teams. The firm is recognized for its analytical rigor, technology infrastructure, and ability to combine market access strategy with broader commercial operations. ZS is most often selected by enterprise pharma teams that want consulting depth alongside ongoing access analytics and field force support.

6. Putnam Associates

Putnam Associates is a strategy consulting firm focused exclusively on the life sciences industry, with strong capabilities in commercial and pricing strategy, market access, and global launch planning.

Putnam's market access services include global market assessments, pricing research, payer interviews, and access strategy across therapeutic areas. As a focused life sciences firm, Putnam works with both established and emerging pharma companies on market access decisions throughout the product lifecycle. The firm is particularly valuable for pharma teams navigating complex multi-market launches where pricing strategy and access dynamics vary significantly across geographies.

7. IQVIA Market Access Solutions

IQVIA Market Access Solutions is the dedicated market access arm of IQVIA, offering payer research, HEOR, real-world evidence, pricing analytics, and market access strategy supported by IQVIA's claims data infrastructure and global market presence.

IQVIA Market Access combines payer research with claims data analytics, real-world evidence generation, and pricing benchmarks across global markets. The firm is particularly valuable for pharma teams that need integrated market access services drawing on IQVIA's claims data, prescription analytics, and global market intelligence. IQVIA Market Access is most often selected by enterprise pharma teams that want market access services tightly integrated with broader IQVIA commercial analytics and data infrastructure.

8. Xcenda (AmerisourceBergen)

Xcenda is the market access and payer research arm of AmerisourceBergen, offering value strategy, HEOR, payer research, and reimbursement consulting backed by AmerisourceBergen's distribution and pharmacy network.

Xcenda's services include value proposition development, payer research, real-world evidence, and access strategy across U.S. and global markets. The firm benefits from AmerisourceBergen's relationships with pharmacies, providers, and payers, providing market access services with strong distribution-channel context. Xcenda is most often selected for engagements where payer research benefits from integration with downstream channel and patient access dynamics.

9. Prescient Healthcare Group

Prescient is a global pharmaceutical consulting firm specializing in strategic insight generation and competitive intelligence, with growing capabilities in market access and payer research.

Prescient supports pharma clients with payer landscape research, competitive market access intelligence, and strategic positioning across therapeutic areas. The firm's strength is in real-time competitive tracking and decision-making support during fast-moving commercial windows. Prescient is particularly valuable for pharma teams navigating crowded or rapidly evolving therapeutic categories where competitive payer dynamics shift quickly.

10. Healthsperien

Healthsperien is a healthcare policy and market access consulting firm specializing in U.S. federal and state policy, Medicare and Medicaid strategy, and reimbursement landscape navigation for pharma and healthcare clients.

Healthsperien supports clients with policy intelligence, market access strategy, federal and state engagement, and reimbursement planning across U.S. public and commercial markets. The firm is recognized for its depth of policy fluency, particularly in Medicare, Medicaid, and federal regulatory frameworks. Healthsperien is most often selected by pharma teams whose products face complex U.S. public-payer dynamics or evolving policy environments that require specialized policy advisory alongside traditional market access work.

Pricing Strategy and Value-Based Pricing Frameworks

Payer research platforms support pharma teams in developing pricing strategies that align with payer value perception, regulatory frameworks, and global market access requirements. Capabilities include value-based pricing analysis, indication-based pricing strategy, conditional pricing frameworks, and pricing benchmarks across therapeutic areas. The strongest platforms combine quantitative pricing modeling with primary payer research to validate pricing assumptions before launch — a workflow that increasingly incorporates synthetic payer modeling for rapid scenario testing.

Health Economics and Outcomes Research (HEOR)

HEOR capabilities are foundational to payer research engagements, supporting pharma teams in demonstrating product value through cost-effectiveness analysis, budget impact modeling, indirect treatment comparisons, and patient-reported outcome measurement. Platforms offer health economics expertise across therapeutic areas, with particular depth in oncology, rare disease, immunology, and chronic conditions. HEOR engagements typically combine model development with payer research validation to ensure economic narratives land with target audiences.

Payer Research and Stakeholder Engagement

Primary payer research is the foundational capability of any market access platform — engaging medical directors, pharmacy directors, formulary committee members, and PBM contracting leaders through structured research. Capabilities include payer interviews, advisory boards, payer panels, and longitudinal payer engagement programs. The strongest platforms maintain ongoing payer relationships rather than recruiting per project, producing higher-quality insights through trusted long-term engagement.

Market Access Strategy and Launch Planning

Market access strategy services help pharma teams design integrated access plans across pricing, contracting, payer engagement, patient support, and channel strategy. This includes pre-launch market access planning, launch readiness assessment, post-launch optimization, and lifecycle access management. Platforms with strong market access strategy capabilities help pharma teams anticipate access dynamics across the product lifecycle rather than reacting to access challenges after launch.

HTA Submissions and Global Reimbursement

Global reimbursement capabilities support pharma teams in navigating health technology assessment bodies — NICE in the UK, IQWiG in Germany, HAS in France, CADTH in Canada, and other national HTA bodies. Capabilities include HTA dossier preparation, reimbursement strategy across markets, value framework alignment, and post-HTA negotiation support. Pharma teams launching globally typically require HTA support across multiple geographies simultaneously.

Real-World Evidence and Value Demonstration

Modern payer research increasingly incorporates real-world evidence to demonstrate value in actual patient populations. Capabilities include longitudinal RWE study design, claims-based analytics, patient-reported outcome programs, and integrated evidence packages combining clinical trial data with real-world performance. RWE capabilities are particularly important for value-based contracting, outcomes-based agreements, and post-launch evidence requirements that increasingly accompany payer access.

Policy Intelligence and Regulatory Navigation

Policy intelligence supports pharma teams in tracking evolving regulatory frameworks, reimbursement policy changes, and access dynamics across U.S. federal and state markets and global geographies. Capabilities include policy monitoring, regulatory analysis, federal and state engagement strategy, and scenario planning for evolving policy environments. Avalere and Healthsperien represent category leaders in U.S. policy intelligence; global firms offer comparable capabilities across European and APAC markets.

Payer Decision Intelligence and Synthetic Modeling

The newest capability in the payer research category is decision intelligence — synthetic modeling of payer response to pricing scenarios, value claims, and access strategies before primary research. Capabilities include payer persona modeling, scenario stress-testing, value proposition optimization, and rapid iteration on pricing strategy. Decision intelligence platforms like Acumen extend the methodology to model payer response alongside HCP, patient, and internal stakeholder dynamics — producing integrated views of access decisions that single-stakeholder research cannot match.

Quick-Turn Payer Pulse Research

Modern payer research platforms support quick-turn methodology for scoped questions where rapid payer feedback is needed — typically 2-3 weeks from kickoff to deliverable. Quick-turn research is most viable for established payer relationships and scoped questions; broader strategic research requires longer timelines. Pharma teams should expect quick-turn payer research to be more limited in scope than comparable HCP or patient research due to the smaller payer audience.

Standard Payer Primary Research

Standard quantitative and qualitative payer research — pricing research, value proposition testing, formulary committee research — typically runs 8-14 weeks from kickoff to deliverable, depending on sample size, geographic coverage, and depth of analysis. Most pharma teams plan for 10 weeks as a working assumption when scoping standard payer research, with longer timelines for global studies spanning multiple markets.

Health Economics Model Development

HEOR model development — cost-effectiveness models, budget impact models, indirect comparisons — typically runs 12-20 weeks depending on model complexity, indication breadth, and validation requirements. Models for HTA submissions often require longer development cycles due to validation against specific HTA methodology requirements. Pharma teams should plan HEOR development concurrent with pivotal trial timelines to ensure models are ready for launch and reimbursement engagements.

HTA Submissions and Global Reimbursement

HTA submission preparation typically runs 6-12 months from initial planning through dossier submission, depending on geography and complexity. Post-submission negotiation can extend timelines significantly. Pharma teams launching globally should plan HTA work beginning 18-24 months before anticipated launch in priority markets.

Synthetic and Decision Intelligence Modeling

Synthetic payer modeling and decision intelligence platforms compress payer scenario testing dramatically. Once calibrated against client research and payer landscape data, individual modeling cycles can run in 24-72 hours from question to deliverable. This is the operational advantage that defines the synthetic and decision intelligence category — making it possible to inform pricing and access decisions inside campaign and quarterly windows that traditional payer research cannot reach.

Launch Readiness and Pre-Launch Access Programs

Comprehensive launch readiness programs combining payer research, HEOR, market access strategy, and HTA preparation typically run 18-36 months in the pre-launch window. Pharma teams should plan launch-readiness market access programs at least 24 months before anticipated launch in priority markets to allow for full research, model development, and stakeholder engagement cycles.

Ongoing Access Operations

Once a brand is launched, payer research operations typically settle into ongoing rhythms — quarterly payer pulse research, ongoing policy monitoring, real-world evidence generation, contract renewal support, and ad hoc research as policy and competitive disruptions emerge. The strongest pharma operations integrate payer research as a continuous intelligence layer rather than discrete project-based engagements.

Project-Based Pricing for Strategy Engagements

Strategy consulting firms (Avalere, Trinity, ClearView, Putnam, ZS, Healthsperien) typically price per engagement, with costs driven by scope, duration, geographic coverage, and senior consultant involvement. Pricing for standard market access strategy engagements typically ranges from $150,000 for scoped advisory work to $1.5M+ for comprehensive multi-market launch readiness programs. Complex global engagements with multi-stakeholder coordination command premium pricing.

Subscription and Platform Licensing

Platform-based offerings (Acumen, ZoomRx, IQVIA Market Access analytics) typically operate on annual subscription models with tiered pricing based on user seats, feature access, and usage volume. Subscription pricing for enterprise market access platforms typically runs $250,000 to $2M annually depending on platform, scope, and team size. Subscription models become more cost-effective as study volume increases.

HEOR Model Development Pricing

HEOR model development typically prices per model, with significant variation based on model complexity, indication breadth, and validation requirements. Standard cost-effectiveness models typically range from $150,000 to $500,000 per model. Complex models supporting global HTA submissions with multi-country adaptation can run substantially higher. Most pharma teams budget for HEOR model development concurrent with launch readiness.

HTA Submission Pricing

HTA submission preparation typically prices per geography, with significant variation based on HTA body requirements and model complexity. Single-geography HTA submissions typically range from $300,000 to $800,000 including model development, dossier preparation, and submission support. Multi-country global HTA programs run substantially higher and typically span 18+ months.

Pilot and Conversion Pricing

Platform-based offerings increasingly include pilot engagements ranging from $50,000 to $150,000 with conversion credit toward annual licensing. Acumen offers 90-day pilots with full conversion credit. Pilot pricing for payer research platforms typically runs higher than HCP or patient research pilots due to the depth of payer landscape calibration required.

Total Cost of Ownership for Market Access

Beyond engagement and licensing fees, total cost of market access operations includes internal team time for briefing and review, integration with broader research workflows, and the ongoing cost of payer relationships and engagement programs. Most enterprise pharma deployments of market access capability run $1M to $5M annually across primary research, HEOR, HTA, policy intelligence, and increasingly decision intelligence platforms — typically the highest-cost research function within pharma commercial operations.

Established Payer Relationships at Scale

Access to established payer relationships is the foundational asset of any credible payer research platform. Avalere's depth of U.S. policy and payer relationships, Trinity's payer engagement infrastructure, IQVIA's global payer access through claims data partnerships — these are assets pharma teams cannot replicate internally and that take years to build. Platform partnerships provide immediate access to payer audiences that would otherwise require dedicated relationship investment.

Therapeutic Area and Geographic Depth

Payer dynamics vary significantly across therapeutic areas and geographies. Specialty oncology payer dynamics differ from chronic condition pricing dynamics. U.S. commercial payer logic differs from European HTA frameworks differs from APAC reimbursement systems. Payer research platforms with deep therapeutic area and geographic calibration produce materially better outputs than generalist tools. Coverage depth is a primary differentiator across the category.

Health Economics and Modeling Expertise

HEOR is technical, methodological work requiring specialized expertise in health economics, biostatistics, and HTA methodology. Pharma teams benefit from external HEOR expertise that brings methodology knowledge across HTA bodies and therapeutic areas, model development experience across product types, and validation expertise that internal teams typically lack. HEOR capability is operationally critical for pharma launches in geographies with HTA frameworks.

Speed Without Sacrificing Methodology

Modern payer research platforms compress traditional timelines while maintaining methodological rigor. Quick-turn payer pulse research, accelerated HEOR model development, AI-augmented payer landscape analysis, and synthetic payer modeling all extend what's possible inside pharma commercial cycles. Speed is increasingly important as competitive launch dynamics compress decision windows.

Compliance and Ethical Infrastructure

Payer research operates within HIPAA, GDPR, sunshine act transparency, FMV honoraria requirements, and pharmaceutical industry codes of conduct. Specialized payer research platforms have built-in compliance infrastructure for payer engagement, honoraria payment, and transparency reporting that pharma procurement requires. Confirming compliance infrastructure during vendor evaluation is non-negotiable for enterprise pharma engagements.

Integration With Existing Pharma Research Stack

The strongest payer research platforms integrate cleanly with the broader pharma research ecosystem — IQVIA claims data, Kantar Health value research, real-world evidence platforms, and proprietary payer research investments. Platforms that operate as additions to existing infrastructure rather than replacements convert more cleanly through enterprise pharma procurement and produce better outputs by leveraging existing data assets.

Multi-Stakeholder Modeling Capability

Modern access decisions don't happen in isolation — they're shaped by HCP demand, patient need, internal organizational dynamics, and competitive positioning. The strongest payer research platforms increasingly model payer behavior in context of these other stakeholders. Decision intelligence platforms like Acumen extend this capability further by modeling payers alongside HCPs, patients, executives, and regulators for the cross-functional decisions that determine access outcomes.

Therapeutic Area and Geographic Coverage

Evaluate vendors specifically against the therapeutic areas and geographies your portfolio covers. A platform with strong U.S. commercial payer depth may have weaker coverage in European HTA work or APAC reimbursement systems. Ask vendors specifically about payer relationships, HTA experience, and historical engagement in your therapeutic areas and target geographies. Coverage fit matters more than overall platform sophistication.

Methodology Mix and Innovation

Modern payer research operations require methodology mix — primary payer research, HEOR modeling, real-world evidence, policy intelligence, and increasingly synthetic payer modeling. Vendors who support multiple methodologies natively are more flexible than vendors who specialize in one approach. Ask which methodologies are platform-native versus partnership-delivered.

Health Economics and HTA Capability

Health economics expertise varies meaningfully across the category. Evaluate HEOR team composition, HTA submission experience across geographies, and methodology depth across therapeutic areas. Vendors with strong HEOR capability typically combine economics expertise with payer relationships and policy intelligence — not just technical modeling.

AI and Synthetic Capability

The payer research category is rapidly incorporating AI augmentation and synthetic modeling. Evaluate where each vendor sits on this spectrum — pure traditional research, AI-augmented analysis on top of payer data, or synthetic-native modeling grounded in payer landscape data. The strongest platforms combine multiple approaches and position AI as augmentation rather than replacement for verified payer voice.

Compliance and Regulatory Infrastructure

Pharma payer research compliance requirements are extensive — HIPAA, sunshine act transparency, FMV honoraria, federal and state regulatory frameworks, and pharmaceutical industry codes. Confirm in writing during evaluation whether the platform has SOC 2 Type II controls, signed BAAs and DPAs as standard practice, and explicit compliance infrastructure for pharmaceutical payer research.

Integration With Existing Research Workflow

The platform should integrate cleanly with the research vendors and tools your team already uses. Ask vendors how they ingest data from existing partners, whether they connect to claims data, real-world evidence platforms, and internal market access intelligence, and how they handle vendor IP and contractual data-sharing requirements.

Pilot Discipline and Conversion Path

Most credible platform-based vendors offer structured pilots with conversion credit toward annual subscription. Strategy consulting firms typically operate on project-based engagement models. Use pilot or initial engagement scoping to evaluate vendor honesty — do they push back on unrealistic use cases, surface coverage gaps proactively, and align scope to real decision use cases?